Literature DB >> 20661622

Cryptococcosis and tuberculosis co-infection at a university hospital in Taiwan, 1993-2006.

C-T Huang1, Y-J Tsai, J-Y Fan, S-C Ku, C-J Yu.   

Abstract

BACKGROUND: The human immunodeficiency virus (HIV) epidemic and increasing use of immunosuppressive agents have increased the prevalence of both cryptococcosis and tuberculosis (TB). However, the status of co-infection with both pathogens remains unknown.
METHODS: This study retrospectively reviewed patient records of cryptococcosis and TB co-infection from 1993 to 2006. The temporal sequence of co-infection was defined as either concurrent or sequential. Data collected included patient demographics, HIV status, co-morbidities, clinical manifestations, treatment strategies, and outcome at 1-year follow-up.
RESULTS: There were 23 patients with cryptococcosis and TB co-infection, representing 5.4% of cryptococcosis or 0.6% of TB cases. Eleven (48%) patients were HIV-infected, and no underlying disease or immunocompromised state could be identified in six (26%) patients. Twelve (52%) patients presented with concurrent infection, but diagnosis of co-infection could be achieved simultaneously in only three (13%). Constitutional symptoms, particularly fever and weight loss, were the most common presenting symptoms, developing in more than two-thirds of the patients. The majority (83%) of the patients made a good recovery following dual antifungal and anti-TB therapy. There were three mortalities at the 1-year follow-up, which might be attributable to a delay in diagnosis and treatment of co-infection. The outcomes of HIV-infected and non-HIV-infected patients were not significantly different.
CONCLUSIONS: Cryptococcosis and TB co-infection, although rare, develops in both immunocompromised and healthy individuals. Early diagnosis and treatment may improve patient prognosis. There should be a high index of suspicion in order to achieve a timely diagnosis in a TB endemic area.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20661622     DOI: 10.1007/s15010-010-0045-9

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  29 in total

1.  Case report. Meningitis due to Cryptococcus neoformans var. neoformans serotype AD associated with pulmonary tuberculosis.

Authors:  S Nagrajan; H C Gugnani; T Kowshik
Journal:  Mycoses       Date:  2000       Impact factor: 4.377

2.  Dual infective pathology in patients with cryptococcal meningitis.

Authors:  E Silber; P Sonnenberg; H J Koornhof; L Morris; D Saffer
Journal:  Neurology       Date:  1998-10       Impact factor: 9.910

Review 3.  Cryptococcal osteomyelitis: case report and review.

Authors:  P Y Liu
Journal:  Diagn Microbiol Infect Dis       Date:  1998-01       Impact factor: 2.803

Review 4.  Idiopathic CD4 lymphocytopenia.

Authors:  Ulrich A Walker; Klaus Warnatz
Journal:  Curr Opin Rheumatol       Date:  2006-07       Impact factor: 5.006

5.  Cryptococcal meningitis in human immunodeficiency virus-infected patients in Harare, Zimbabwe.

Authors:  R S Heyderman; I T Gangaidzo; J G Hakim; J Mielke; A Taziwa; P Musvaire; V J Robertson; P R Mason
Journal:  Clin Infect Dis       Date:  1998-02       Impact factor: 9.079

6.  Treatment outcomes of patients with HIV and tuberculosis.

Authors:  Payam Nahid; Leah C Gonzalez; Irina Rudoy; Bouke C de Jong; Alon Unger; L Masae Kawamura; Dennis H Osmond; Philip C Hopewell; Charles L Daley
Journal:  Am J Respir Crit Care Med       Date:  2007-02-08       Impact factor: 21.405

7.  Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice.

Authors:  J L Flynn; M M Goldstein; J Chan; K J Triebold; K Pfeffer; C J Lowenstein; R Schreiber; T W Mak; B R Bloom
Journal:  Immunity       Date:  1995-06       Impact factor: 31.745

8.  Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years--United States, 2008.

Authors:  Eileen Schneider; Suzanne Whitmore; Kathleen M Glynn; Kenneth Dominguez; Andrew Mitsch; Matthew T McKenna
Journal:  MMWR Recomm Rep       Date:  2008-12-05

Review 9.  Treatment Options for HIV-Associated Tuberculosis.

Authors:  Philip Chukwuka Onyebujoh; Isabela Ribeiro; Christopher Curtis Whalen
Journal:  J Infect Dis       Date:  2007-08-15       Impact factor: 5.226

Review 10.  Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome.

Authors:  Helen McIlleron; Graeme Meintjes; William J Burman; Gary Maartens
Journal:  J Infect Dis       Date:  2007-08-15       Impact factor: 5.226

View more
  10 in total

1.  Concurrent cryptococcal meningitis and disseminated tuberculosis occurring in an immunocompetent male.

Authors:  Marcellin Musabende; Constance Mukabatsinda; Elisabeth D Riviello; Onyema Ogbuagu
Journal:  BMJ Case Rep       Date:  2016-02-25

2.  A Case of Disseminated Cryptococcal Infection and Concurrent Lung Tuberculosis in a Patient under Steroid Therapy for Interstitial Pneumonia.

Authors:  Aoi Kuroda; Sadatomo Tasaka; Kazuma Yagi; Takao Mochimaru; Tetsuo Tani; Ho Namkoong; Kyuto Tanaka; Yusuke Suzuki; Mami Hatano; Naoki Hasegawa; Yasunori Okada; Tomoko Betsuyaku
Journal:  Case Rep Pulmonol       Date:  2015-06-01

3.  Cryptococcosis and tuberculosis co-infection in mainland China.

Authors:  Min Chen; Abdullah Ms Al-Hatmi; Yuchong Chen; Yang Ying; Wenjie Fang; Jianping Xu; Ferry Hagen; Nan Hong; Teun Boekhout; Wanqing Liao; Weihua Pan
Journal:  Emerg Microbes Infect       Date:  2016-09-07       Impact factor: 7.163

Review 4.  Tuberculosis/cryptococcosis co-infection in China between 1965 and 2016.

Authors:  Wenjie Fang; Lei Zhang; Jia Liu; David W Denning; Ferry Hagen; Weiwei Jiang; Nan Hong; Shuwen Deng; Xia Lei; Danqi Deng; Wanqing Liao; Jianping Xu; Teun Boekhout; Min Chen; Weihua Pan
Journal:  Emerg Microbes Infect       Date:  2017-08-23       Impact factor: 7.163

5.  Molecular epidemiology of cryptococcal genotype VNIc/ST5 in Siriraj Hospital, Thailand.

Authors:  Chanin Hatthakaroon; Sujiraphong Pharkjaksu; Piriyaporn Chongtrakool; Kamol Suwannakarn; Pattarachai Kiratisin; Popchai Ngamskulrungroj
Journal:  PLoS One       Date:  2017-03-21       Impact factor: 3.240

6.  Comparison of real time IS6110-PCR, microscopy, and culture for diagnosis of tuberculous meningitis in a cohort of adult patients in Indonesia.

Authors:  Lidya Chaidir; Ahmad Rizal Ganiem; Adri Vander Zanden; Soni Muhsinin; Tina Kusumaningrum; Inri Kusumadewi; Andre van der Ven; Bachti Alisjahbana; Ida Parwati; Reinout van Crevel
Journal:  PLoS One       Date:  2012-12-21       Impact factor: 3.240

7.  Cryptococcal Pleuritis Presenting with Lymphocyte-predominant and High Levels of Adenosine Deaminase in Pleural Effusions Coincident with Pulmonary Tuberculosis.

Authors:  Yoshitomo Kushima; Hidenori Takizawa; Yasutaka Machida; Takafumi Umetsu; Naoya Ikeda; Masaaki Miyoshi; Kazuyuki Chibana; Yasuo Shimizu; Akihiro Takemasa; Yoshiki Ishii
Journal:  Intern Med       Date:  2017-10-11       Impact factor: 1.271

8.  Tuberculous peritonitis and pleurisy accompanied by pulmonary cryptococcosis: A case report.

Authors:  Jian-Kun Chen; Shu-Bin Cai; Qian Cai; Hang Qi; Ji-Qiang Li
Journal:  J Int Med Res       Date:  2018-05-13       Impact factor: 1.671

9.  Cryptococcal Meningitis and Tuberculous Meningitis Co-infection in HIV-Infected Ugandan Adults.

Authors:  Jayne Ellis; Fiona V Cresswell; Joshua Rhein; Kenneth Ssebambulidde; David R Boulware
Journal:  Open Forum Infect Dis       Date:  2018-08-29       Impact factor: 3.835

10.  Tuberculosis in HIV-Associated Cryptococcal Meningitis is Associated with an Increased Risk of Death.

Authors:  Morris K Rutakingirwa; Fiona V Cresswell; Richard Kwizera; Kenneth Ssebambulidde; Enock Kagimu; Edwin Nuwagira; Lillian Tugume; Edward Mpoza; Joanna Dobbin; Darlisha A Williams; Conrad Muzoora; David B Meya; David R Boulware; Kathy H Hullsiek; Joshua Rhein
Journal:  J Clin Med       Date:  2020-03-13       Impact factor: 4.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.